Ipsen on Tuesday announced Dr Steven Hildemann as its new Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance.
The appointment will be effective from March 1, 2020, and Dr Hildemann will report directly to the company’s CEO Aymeric Le Chatelier.
Based in Paris, he will act as a strategic partner to Ipsen’s scientific, clinical and business teams and also serve on the company’s Executive Leadership Team.
“As we advance as a leading global biopharmaceutical company focused on innovation and Specialty Care, it is my great pleasure to appoint Dr Hildemann to lead Ipsen’s Global Medical Affairs, Patient Affairs and Pharmacovigilance organizations through patient-centric leadership, sound medical governance and business conduct,” said Aymeric Le Chatelier, CEO, Ipsen.
“Dr Hildemann will play a crucial role in delivering on our global medical and patient safety strategy, engaging in structured, ethical and high-quality dialogue with patients, external and internal stakeholders throughout the entire life-cycle of Ipsen’s portfolio.”
Before joining Ipsen, Dr Hildemann held leadership roles in science-based bioethics and built a digital startup in cancer care. He also served five years as Chief Medical Officer, Senior Vice President, Head of Global Medical Affairs and Global Patient Safety at Merck, and held several leadership positions with companies such as Pharmacia-Pfizer and Schering-Plough-MSD.
